USA-based Novavax (Nasdaq: NVAX) is beginning the week with its share price almost 85% lower than last week after the failure of its respiratory syncytial virus (RSV) F-protein recombinant nanoparticle vaccine candidate in older adults in a trial.
The vaccines specialist announced the news from the Resolve Phase III trial on Thursday, sending the value of its shares from $8.32 to around $1.20.
Neither the pre-specified primary or secondary efficacy objectives of the trial were met.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze